AEMD vs XTLB vs EKSO vs PRTH vs TELA

For growth investors, TELA Bio, Inc.

(TELA) is the stronger pick with 18. 6% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Priority Technology Holdings, Inc. (PRTH) offers the better valuation at 8. 1x trailing P/E (5. 8x forward), making it the more compelling value choice. Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Priority Technology Holdings, Inc.

(PRTH) delivered a total return of -15. 9%, compared to -99. 8% for Aethlon Medical, Inc. (AEMD). Over 10 years, the gap is even starker: PRTH returned -43. 8% versus AEMD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TELA Bio, Inc.

(TELA) is the lower-risk stock at 0. 57β versus Priority Technology Holdings, Inc. 's 2. 12β — meaning PRTH is approximately 271% more volatile than TELA relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 151% for TELA Bio, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TELA Bio, Inc.

(TELA) is pulling ahead at 18. 6% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: Priority Technology Holdings, Inc. grew EPS 319. 4% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, TELA leads at 33. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Priority Technology Holdings, Inc.

(PRTH) is the more profitable company, earning 5. 8% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 5. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRTH leads at 14. 8% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — TELA leads at 67. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRTH: 99.

6% to $11. 00.

In this comparison, EKSO (0.

8% yield) pays a dividend. AEMD, XTLB, PRTH, TELA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TELA Bio, Inc.

(TELA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57)). Priority Technology Holdings, Inc. (PRTH) carries a higher beta of 2. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TELA: -91. 8%, PRTH: -43. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AEMD (Healthcare) and XTLB (Healthcare) and EKSO (Healthcare) and PRTH (Technology) and TELA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AEMD is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; EKSO is a small-cap quality compounder stock; PRTH is a small-cap deep-value stock; TELA is a small-cap high-growth stock. EKSO pays a dividend while AEMD, XTLB, PRTH, TELA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.